Business
Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Nataliya Agafonova Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan drug designation, and Fast track designationLaromestrocel HLHS progra
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Nataliya Agafonova","length":18,"tagName":"p"},{"type":"image","alt":"Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron","displaySize":"","headline":null,"caption":"Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":109,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/025b5ef53f21da23bcd9028e2d842f1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D0k9wSAfkbUqGepOFlp68A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIyOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/025b5ef53f21da23bcd9028e2d842f1a","width":109,"height":119}}},{"type":"list","items":[{"val":[{"type":"text","content":"Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-months","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are positive","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan drug designation, and Fast track designation","length":135,"tagName":"p"}]},{"val":[{"type":"text","content":"Laromestrocel HLHS program addresses unmet medical needs with U.S. market potential of up to $1 billion","length":103,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":499,"olType":false},{"type":"text","content":"MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has achieved full enrollment of the Phase 2b clinical trial (...